Optorain Obtains A·A in Special Listing Technical Evaluation... Green Light for KOSDAQ Listing

Optorain, a semiconductor-based bio convergence next-generation diagnostic platform company (CEO: Do-Young Lee), announced on the 8th that it has officially entered the initial public offering (IPO) process by obtaining A and A grades in the technology evaluation for KOSDAQ special listing.

For a KOSDAQ special technology listing, a company must receive an A grade and at least a BBB grade in technology evaluations from two specialized evaluation institutions designated by the Korea Exchange. Optorain received excellent evaluations in terms of technology completeness and various aspects from the Korea Invention Promotion Association and the Korea Technology Credit Rating Agency, achieving technology evaluation grades of ‘A, A’. Based on this technology evaluation, Optorain plans to submit the preliminary listing examination application and list within this year.

Founded in 2012, Optorain is a company developing next-generation diagnostic platforms by converging system semiconductor technology and bio technology. Its main businesses include providing various diagnostic solutions such as ▲precision diagnostic solutions related to cancer ▲multiplex rapid point-of-care diagnostic solutions for infectious diseases.

Additionally, Optorain’s diagnostic platform is an open platform that offers highly scalable solutions allowing participation from various industries. It has secured numerous platform participation cases including ▲diagnostic companies’ reagent or diagnostic service development ▲pharmaceutical companies’ therapeutic development ▲environmentally friendly solution development by pest control companies. Optorain plans to strengthen platform capabilities and expand the open platform business based on these participation cases.

Do-Young Lee, CEO of Optorain, stated, “We will lead bio localization and diversify the use of system semiconductors by supplying next-generation diagnostic platforms based on world-class technology. Based on this technology evaluation, we will pursue a KOSDAQ listing within this year to establish a more stable financial structure and further enhance corporate value through technology advancement.”

Meanwhile, in December last year, Optorain announced a blood cancer diagnostic solution with world-class sensitivity at the American Society of Hematology (ASH) and is accelerating overseas expansion and market development through point-of-care diagnostic solutions.